T25
Glucocorticoids (GCs) are widely used in treatment of many cancer types due to its ability to induce apoptosis in malignant cells in blood cancer therapy, and to prevent nausea, emesis and chemotherapy-associated hepatotoxicity in case of solid tumors. However, severe dose-limiting side effects occu...
Main Authors: | E. Lesovaya, L. Tilova, O. Zadorozhnaya, A. Savinkova, K. Kirsanov, A. Ogloblina, G. Belitsky, G. Baida, I. Budunova, M. Yakubovskaya |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2015-11-01
|
Series: | EJC Supplements |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1359634915000609 |
Similar Items
-
P85
by: L. Tilova, et al.
Published: (2015-11-01) -
Trabectedin – the DNA minor groove binder
by: G. A. Belitsky, et al.
Published: (2015-06-01) -
Mechanisms of carcinogenesis prevention by flavonoids
by: G. A. Belitsky, et al.
Published: (2015-06-01) -
INHIBITION OF REDD1 EXPRESSION FOR THE REDUCTION OF GLUCOCORTICOID-INDUCED SIDE EFFECTS
by: E. S. Lylova, et al.
Published: (2020-12-01) -
T140
by: M. Yakubovskaya, et al.
Published: (2015-11-01)